ALX Oncology Holdings Inc. (ALXO)

ALX Oncology Holdings Inc. (ALXO) Healthcare & Pipeline Overview

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on the development of ALX148, a CD47 blocking therapeutic, for the treatment of various cancers. The company collaborates with industry leaders like Merck and Zymeworks to advance its clinical trials and expand its therapeutic applications.

What Is the Investment Thesis for ALXO?

ALX Oncology presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's lead drug candidate, ALX148, targets the CD47 pathway, a promising area in cancer immunotherapy. Positive data from ongoing Phase 1b/2 clinical trials could serve as a significant catalyst, driving up the company's valuation. Collaborations with Merck and Zymeworks provide validation of ALX148's potential and offer access to resources and expertise. However, the company faces significant challenges, including the inherent risks associated with clinical-stage drug development, potential competition from other CD47-targeting therapies, and the need for substantial capital to fund ongoing research and development. The company's market cap of $302.09M reflects the speculative nature of its future prospects. Investors should closely monitor clinical trial results and partnership developments to assess the company's progress and potential for long-term value creation.

Based on FMP financials and quantitative analysis

ALXO Key Highlights

• ALX148 is in Phase 1b/2 clinical trials for myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and various solid tumors.
• Collaboration agreement with Merck to evaluate ALX148 in combination with pembrolizumab for head and neck cancer.
• Partnership with Zymeworks for a Phase 1 trial assessing ALX148 with zanidatamab in HER2-expressing breast cancer and other solid tumors.
• Pre-clinical product ALTA-002 aims to engage the innate and adaptive immune response to cancer.
• Market capitalization of $302.09M reflects the company's clinical-stage status and future growth potential.

Who Are ALXO's Competitors?

ALXO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALXO's Key Strengths?

• Novel CD47-blocking technology.
• Strategic collaborations with Merck and Zymeworks.
• Experienced management team.
• ALX148 is in Phase 1b/2 clinical trials.

What Are ALXO's Weaknesses?

• Clinical-stage company with no approved products.
• Limited financial resources.
• High dependence on the success of ALX148.
• Small number of employees.

What Could Drive ALXO Stock Higher?

• Data readout from Phase 1b/2 clinical trials of ALX148 in myelodysplastic syndromes.
• Announcement of new partnerships or collaborations.
• Enrollment of patients in ongoing clinical trials.
• Advancement of ALTA-002 into clinical development.

What Are the Key Risks for ALXO?

• Financial-distress signal — its Altman Z-Score of -0.39 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Competition from other CD47-targeting therapies.
• Regulatory hurdles and delays in obtaining approvals.
• Dependence on the success of ALX148.
• Need for significant capital to fund research and development.

What Are the Growth Opportunities for ALXO?

• Expansion of ALX148 into new indications: ALX Oncology has the opportunity to expand the use of ALX148 into additional cancer types beyond its current clinical trials. This includes exploring its potential in other solid tumors and hematological malignancies. The market for cancer therapies is substantial, with global oncology sales projected to reach $250 billion by 2024. Successful clinical trials in new indications could significantly increase ALX Oncology's market opportunity and revenue potential.
• Advancement of ALTA-002 into clinical development: ALX Oncology's pre-clinical product, ALTA-002, represents another growth opportunity. By advancing ALTA-002 into clinical trials, the company can diversify its pipeline and target a broader range of immune responses to cancer. The market for novel immunotherapies is growing rapidly, driven by the need for more effective and less toxic cancer treatments. Positive results from pre-clinical studies and early clinical trials could attract further investment and partnerships.
• Strategic collaborations and partnerships: ALX Oncology can leverage strategic collaborations and partnerships to accelerate the development and commercialization of its therapies. The company's existing collaborations with Merck and Zymeworks demonstrate its ability to attract partnerships with leading pharmaceutical companies. Future collaborations could provide access to additional funding, expertise, and resources, enabling ALX Oncology to expand its research and development efforts and reach a wider patient population.
• Out-licensing or acquisition of ALX148: ALX Oncology could pursue out-licensing or acquisition of ALX148 by a larger pharmaceutical company. This would provide the company with upfront payments, milestone payments, and royalties on future sales. The market for CD47-blocking therapeutics is attracting significant interest from pharmaceutical companies seeking to expand their immuno-oncology portfolios. A successful out-licensing or acquisition deal could provide ALX Oncology with substantial financial resources to further develop its pipeline and pursue other strategic initiatives.
• Expansion into new geographic markets: ALX Oncology has the opportunity to expand its operations into new geographic markets, particularly in Asia and Europe. These markets offer significant growth potential due to increasing cancer incidence and growing demand for innovative cancer therapies. Establishing a presence in these markets would require significant investment in clinical trials, regulatory approvals, and commercial infrastructure. However, the potential rewards could be substantial, providing ALX Oncology with access to a larger patient population and increased revenue streams.

What Opportunities Does ALXO Have?

• Expansion of ALX148 into new indications.
• Advancement of ALTA-002 into clinical development.
• Potential for out-licensing or acquisition.
• Growing demand for immuno-oncology therapies.

What Threats Does ALXO Face?

• Competition from other CD47-targeting therapies.
• Clinical trial failures.
• Regulatory hurdles.
• Difficulty in raising capital.

What Are ALXO's Competitive Advantages?

• Proprietary CD47-blocking technology with ALX148.
• Strong intellectual property portfolio protecting its therapies.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in immuno-oncology.

What Does ALXO Do?

Founded in 2015 and headquartered in South San Francisco, California, ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative therapies for patients battling cancer. The company's primary focus is on harnessing the power of the immune system to fight cancer more effectively. Its lead product candidate, ALX148, is a CD47 blocking therapeutic currently in Phase 1b/2 clinical trials. ALX148 is being evaluated for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. Additionally, it is being investigated for a range of solid tumor indications, including head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. ALX Oncology is also developing pre-clinical products, including ALTA-002, a SIRPa TRAAC designed to engage both the innate and adaptive immune responses against cancer. The company has established strategic collaborations with industry giants such as Merck, Zymeworks, and Tallac Therapeutics to accelerate the development and commercialization of its therapies. These collaborations focus on evaluating ALX148 in combination with other cancer treatments and developing novel immunotherapeutic approaches. ALX Oncology's commitment to innovation and strategic partnerships positions it as a key player in the rapidly evolving field of immuno-oncology.

What Products and Services Does ALXO Offer?

• Develops immuno-oncology therapies for cancer patients.
• Focuses on CD47 blocking therapeutics.
• Conducts Phase 1b/2 clinical trials for ALX148.
• Targets myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma.
• Investigates ALX148 for solid tumor indications like head and neck squamous cell carcinoma.
• Develops pre-clinical products like ALTA-002, a SIRPa TRAAC.
• Collaborates with Merck, Zymeworks, and Tallac Therapeutics for therapy development.

How Does ALXO Make Money?

• Develops and patents novel immuno-oncology therapies.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.
• Partners with pharmaceutical companies for co-development and commercialization.
• Out-licenses or sells its therapies to generate revenue.

What Industry Does ALXO Operate In?

ALX Oncology operates within the competitive and rapidly evolving immuno-oncology market. This market is characterized by significant innovation and the development of novel therapies that harness the body's immune system to fight cancer. Key trends include the development of checkpoint inhibitors, cell therapies, and targeted immunotherapies. ALX Oncology's focus on CD47-blocking therapeutics positions it within a specific niche of this market. The company faces competition from larger pharmaceutical companies and other biotechnology firms developing similar therapies. The immuno-oncology market is projected to continue to grow, driven by increasing cancer incidence and advancements in understanding the immune system's role in cancer development.

Who Are ALXO's Key Customers?

• Cancer patients in need of new treatment options.
• Hospitals and oncology clinics that administer cancer therapies.
• Pharmaceutical companies that partner with ALX Oncology for drug development.
• Research institutions involved in cancer research.

Company Profile

ALX Oncology Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jason W. Lettmann. ALXO has traded publicly since 2020.

F-Score 3/9Financial Health

ALX Oncology Holdings Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.39 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -49.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -86.2%, the inverse of the P/E and a quick read on earnings relative to price.

ALXO Valuation & Market Position

With a $302.09M market cap, ALX Oncology Holdings Inc. sits in the small-cap segment of the market. Relative to its peer group, ALXO's quantitative score of 33/100 is below the peer average of 70/100.

FY2026 estForward Outlook

Wall Street analysts project ALX Oncology Holdings Inc. revenue of about $4.6M for fiscal 2026, with EPS near $-0.61. The estimate reflects 5 contributing analysts.

ALXO Financials

ALXO Latest News

ALXO Analyst Consensus

ALXO MoonshotScore

Common Questions About ALXO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources